<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527085</url>
  </required_header>
  <id_info>
    <org_study_id>20010141</org_study_id>
    <nct_id>NCT00527085</nct_id>
  </id_info>
  <brief_title>12-month Study of AMG 073 in Renal Osteodystrophy</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      4 doses of AMG 073 or placebo over 52 weeks after a 30-day screening period. Throughout the
      study, labs will be drawn to measure analytes such as iPTH and corrected calcium. In
      addition, a bone biopsy will be performed at screening and at the end of study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of AMG 073 compared with placebo on renal osteodystrophy as assessed by bone histomorphometry</measure>
    <time_frame>entire study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of AMG 073 compared with placebo on intact parathyroid hormone (iPTH), bone-specific alkaline phosphatase (BALP), serum N-Telopeptide (N-Tx), and calcium x phosphorus product concentrations</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the feasibility of measuring physical activity with accelerometry</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of AMG 073 compared with placebo</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Renal Osteodystrophy</condition>
  <arm_group>
    <arm_group_label>AMG 073</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 073</intervention_name>
    <description>30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally</description>
    <arm_group_label>AMG 073</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age of greater

          -  Using effective contraceptive measures

          -  iPTH greater than or equal to 300 pg/mL

          -  Serum Calcium greater than or equal to 8.4 mg/dL; Hemoglobin greater than 9

          -  Stable hemodialysis for 1 month prior to day 1

        Exclusion Criteria:

          -  Any unstable medical condition

          -  Pregnant or nursing women Recent parathyroidectomy

          -  Change in Vitamin D therapy

          -  Recent MI, Seizure, Malignancy, GI Disorder

          -  Inability to swallow tablets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.sensipar.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Malluche HH, Monier-Faugere MC, Wang G, Fraz√£ O JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008 Apr;69(4):269-78.</citation>
    <PMID>18397701</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

